Advertisement
Canada markets close in 1 hour 46 minutes

  • S&P/TSX

    21,870.76
    -140.96 (-0.64%)
     

  • S&P 500

    5,067.83
    -2.72 (-0.05%)
     

  • DOW

    38,454.97
    -48.72 (-0.13%)
     

  • CAD/USD

    0.7296
    -0.0024 (-0.33%)
     

  • CRUDE OIL

    82.57
    -0.79 (-0.95%)
     

  • Bitcoin CAD

    88,717.92
    -2,785.87 (-3.04%)
     

  • CMC Crypto 200

    1,401.32
    -22.78 (-1.60%)
     

  • GOLD FUTURES

    2,336.70
    -5.40 (-0.23%)
     

  • RUSSELL 2000

    1,995.87
    -6.78 (-0.34%)
     

  • 10-Yr Bond

    4.6580
    +0.0600 (+1.30%)
     

  • NASDAQ

    15,703.77
    +7.13 (+0.05%)
     

  • VOLATILITY

    15.68
    -0.01 (-0.06%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

Clearside Biomedical, Inc.
·1 min read
Clearside Biomedical, Inc.
Clearside Biomedical, Inc.

ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 9:30 a.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2 clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.